248
Participants
Start Date
March 31, 2007
Primary Completion Date
August 31, 2008
Study Completion Date
June 30, 2011
Nilotinib
Nilotinib 400 mg twice daily (bid)
Best Supportive Care (BSC) +/- imatinib or sunitinib
Can include pain medication, localized radiotherapy, nutritional support, and/or oxygen therapy and blood transfusions. Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.
Novartis Investigative Site, East Melbourne
Novartis Investigative Site, Auchenflower
St. Vincent's Comprehensive Cancer Center, New York
H. Lee Moffitt Cancer Center, Tampa
Wayne State University/Wertz Clinical Cancer Center, Detroit
University of Chicago Hospital, Chicago
Washington University School of Medicine - Siteman Cancer Center, St Louis
UCLA's Jonsson Comprehensive Cancer Center, Los Angeles
Washington Hospital Center - Washington Cancer Institute, Washington D.C.
Dana Farber Cancer Institute, Boston
Wake Forest University Health Sciences, Winston-Salem
Fox Chase Cancer Center, Philadelphia
University of Texas/MD Anderson Cancer Center, Houston
Novartis Investigative Site, Vienna
Novartis Investigative Site, Toronto
Novartis Investigative Site, Prague
Novartis Investigative Site, Bordeaux
Novartis Investigative Site, Lyon
Novartis Investigative Site, Marseille
Novartis Investigative Site, Berlin
Novartis Investigative Site, Cologne
Novartis Investigative Site, Düsseldorf
Novartis Investigative Site, Essen
Novartis Investigative Site, Frankfurt
Novartis Investigative Site, Hanover
Novartis Investigative Site, Mannheim
Novartis Investigative Site, München
Novartis Investigative Site, Tübingen
Novrtis Investigative Site, Bologna
Novartis Investigative Site, Milan
Novartis Investigative Site, Leiden
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Seoul
Novartis Investigative Site, Madrid
Novartis Investigative Site, Chur
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY